Maridebart Cafraglutide for Obesity
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a new treatment called maridebart cafraglutide, a potential drug for weight management, to observe its behavior in the body when administered as a single dose to individuals with overweight or obesity. Researchers compare two different administration methods to determine which is more effective. This study suits individuals with a body mass index (BMI) between 25 and 40 who do not have diabetes or certain other health conditions. As a Phase 1 trial, the research focuses on understanding how the treatment works in people, offering participants the opportunity to be among the first to receive this new treatment.
Will I have to stop taking my current medications?
Yes, you will need to stop taking any over-the-counter or prescription medications at least 30 days before the trial, unless the investigator approves otherwise. This includes herbal medicines, vitamins, and supplements.
Is there any evidence suggesting that this trial's treatments are likely to be safe?
Research has shown that maridebart cafraglutide was safe in earlier studies. In one study, researchers found no unexpected safety problems. Patients tolerated the treatment well, and the side effects were manageable. This suggests the drug is relatively safe for people at this stage. However, as this trial remains in an early phase, researchers continue to collect safety information. More research is needed to confirm these results.12345
Why do researchers think this study treatment might be promising for obesity?
Maridebart Cafraglutide is unique because it offers a fresh approach to treating obesity by potentially enhancing how the body manages weight. Unlike current treatments like lifestyle changes, medications such as orlistat, or GLP-1 receptor agonists like semaglutide, this drug works by using a new active ingredient that might stimulate weight loss in a different way. Researchers are particularly excited about its novel delivery method, which could improve how effectively the body absorbs the treatment, potentially leading to better results for individuals struggling with obesity.
What evidence suggests that maridebart cafraglutide might be an effective treatment for obesity?
Research has shown that maridebart cafraglutide may aid in weight loss. In earlier studies, individuals with obesity lost an average of up to 20% of their weight. For those with both obesity and type 2 diabetes, the weight loss averaged about 17%. This trial will test two different presentations of maridebart cafraglutide. The treatment imitates a hormone that reduces hunger and manages blood sugar levels. Early results suggest it could effectively help people with obesity lose a significant amount of weight.13678
Who Is on the Research Team?
MD
Principal Investigator
Amgen
Are You a Good Fit for This Trial?
This trial is for individuals living with overweight or obesity. Specific details about who can join are not provided, but typically participants must meet certain health criteria and be within a specific age range.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive a single dose of maridebart cafraglutide using one of two SC presentations
Follow-up
Participants are monitored for safety and pharmacokinetics after receiving the single dose
What Are the Treatments Tested in This Trial?
Interventions
- Maridebart Cafraglutide
Find a Clinic Near You
Who Is Running the Clinical Trial?
Amgen
Lead Sponsor
Robert A. Bradway
Amgen
Chief Executive Officer since 2012
MBA from Harvard Business School
Paul Burton
Amgen
Chief Medical Officer since 2023
MD from University of London, PhD in Molecular and Cellular Biology from Imperial College London